amarin6k_011110.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For the
month of January, 2010.
Commission
File Number 0-21392
(Translation
of registrant's name into English)
First
Floor, Block 3, The Oval, Shelbourne Road, Ballsbridge, Dublin 4, Ireland
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F:
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Note:
Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K
if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Note:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant's "home country"), or under the rules of the home country exchange on
which the registrant's securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant's security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If "Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
This
report on Form 6-K is hereby incorporated by reference in (a) the
registration statement on Form F-3 (Registration No. 333-104748) of Amarin
Corporation plc and in the prospectus contained therein, (b) the
registration statement on Form F-3 (Registration No. 333-13200) of Amarin
Corporation plc and in the prospectus contained therein, (c) the
registration statement on Form F-3 (Registration No. 333-12642) of Amarin
Corporation plc and in the prospectus contained therein, (d) the registration
statement on Form F-3 (Registration No. 333-121431) of Amarin Corporation plc
and in the prospectus contained therein, (e) the registration statement on Form
F-3 (Registration No. 333-121760) of Amarin Corporation plc and in the
prospectus contained therein, (f) the registration statement on Form F-3
(Registration No. 333-135718) of Amarin Corporation plc and in the prospectus
contained therein, (g) the registration statement on Form F-3 (Registration No.
333-131479) of Amarin Corporation plc and in the prospectus contained therein
and (h) the registration statement on Form F-3 (Registration No. 333-151986) of
Amarin Corporation plc and in the prospectus contained therein, and this report
on Form 6-K shall be deemed a part of each such registration statement from the
date on which this report is filed, to the extent not superseded by documents or
reports subsequently filed or furnished by Amarin Corporation plc under the
Securities Act of 1933 or the Securities Exchange Act of 1934.
EXHIBIT
LIST
|
Exhibit
|
Description
|
|
|
|
|
99.1
|
Press
release dated January 11, 2010 titled:
|
|
|
Amarin
Corporation announces first patients enrolled in two Phase 3 clinical
trials assessing AMR101 for the treatment of cardiovascular
disease.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
AMARIN
CORPORATION PLC
|
|
|
|
By:
/s/ John F. Thero
|
|
John
F. Thero
|
|
Chief
Financial Officer
|
Date:
January 11, 2010